RGNX Stock Analysis: Buy, Sell, or Hold?
RGNX - REGENXBIO Inc.
$9.78
-1.42 (-12.72%)
▼
5d:
-29.93%
30d:
+41.05%
90d:
+6.37%
WAIT
LOW Confidence
Analysis Updated: Jul 16, 2026 12:00 AM ET
Earnings: Aug 06, 2026
19d
Get Alerted When RGNX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RGNX is down 29.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RGNX is down 29.9% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RGNX is currently trading at $9.78, which is considered fair relative to its 30-day fair value range of $7.43 to $13.63.
Technical Outlook: Technically, RGNX is in a downtrend. The price is currently testing key support at $11.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 12.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $24.36 (+117.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGNX is in a downtrend. The price is currently testing key support at $11.02. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 12.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $24.36 (+117.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$7.43 -
$13.63
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-12.7%)
- BULLISH: Trading 117.5% below Wall St target ($24.36)
- WARNING: Recommendation downgraded due to -29.9% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$7.43 -
$13.63
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$11.02
Resistance Level
$15.88
Current Trend
Downtrend
Technical data as of
Jul 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.35
Wall Street Target
$24.36
(+117.5%)
Revenue Growth (YoY)
-92.8%
Share & Embed Analysis
Last updated: July 17, 2026 11:10 AM ET
Data refreshes hourly during market hours. Next update: 12:10 PM
Data refreshes hourly during market hours. Next update: 12:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGNX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Steve Pakola
SELL
5124 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 52 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
